Screener
Denali Therapeutics Inc. DNLI EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Denali Therapeutics Inc.’s reported figures.
Based on trailing twelve months.
The source filing: Denali Therapeutics Inc.’s 10-Q, filed August 11, 2025. Open the filing →
- Filed
- Aug 11, 2025
- Fiscal quarter
- Q2 FY2025
- Calendar quarter
- Q2 2025
- Accession
- 0001714899-25-000170
FAQ
- What is Denali Therapeutics Inc.'s EBITDA margin?
- Denali Therapeutics Inc. (DNLI) reported EBITDA margin of -37,267.3% in Q2 2024.
- How has Denali Therapeutics Inc.'s EBITDA margin changed year-over-year?
- Denali Therapeutics Inc.'s EBITDA margin decreased by 88329.0% year-over-year, from -42.1% to -37,267.3%.
- What is the long-term trend for Denali Therapeutics Inc.'s EBITDA margin?
- Over 3 years (2020 to 2023), Denali Therapeutics Inc.'s EBITDA margin has grown at a 36.9% compound annual growth rate (CAGR), from 21.2% to -54.4%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.
Ask your AI about Denali Therapeutics Inc.'s ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude